Published in
Elsevier, European Journal of Cancer, (115), p. 97-106, 2019
DOI: 10.1016/j.ejca.2019.04.020
Links
Tools
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
Journal article published in 2019 by
David Malka,
Eric François,
Frédérique Penault-Llorca,
Florence Castan,
Olivier Bouché,
Jaafar Bennouna 
,
François Ghiringhelli,
Christelle de la Fouchardière ,
Christophe Borg,
Emmanuelle Samalin,
Jean-Baptiste Bachet ,
Jean-Luc Raoul,
Laurent Miglianico,
Leila Bengrine-Lefèvre,
Laetitia Dahan
and other authors.
,
François Ghiringhelli,
Christelle de la Fouchardière ,
Christophe Borg,
Emmanuelle Samalin,
Jean-Baptiste Bachet ,
Jean-Luc Raoul,
Laurent Miglianico,
Leila Bengrine-Lefèvre,
Laetitia Dahan
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 